| 臺大學術典藏 |
2021-02-02T00:47:00Z |
Complete response of urothelial carcinoma to chemotherapy in renal allograft recipients: A two-case study
|
Lin C.-C.;Hsu C.-H.;Yeong-Shiau Pu; Lin C.-C.; Hsu C.-H.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-02-02T00:46:59Z |
Phase II Trial of Weekly Paclitaxel, Cisplatin Plus Infusional High Dose 5-Fluorouracil and Leucovorin for Metastatic Urothelial Carcinoma
|
Lin C.-C.;Hsu C.-H.;Huang C.-Y.;Cheng A.-L.;Vogelzang N.J.;Yeong-Shiau Pu; Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Cheng A.-L.; Vogelzang N.J.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-02-02T00:46:57Z |
Prognostic Factors for Metastatic Urothelial Carcinoma Treated with Cisplatin and 5-Fluorouracil-Based Regimens
|
Lin C.-C.;Hsu C.-H.;Huang C.-Y.;Tsai Y.-C.;Huang K.-H.;Cheng A.-L.;Yeong-Shiau Pu; Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Tsai Y.-C.; Huang K.-H.; Cheng A.-L.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-02-02T00:46:57Z |
Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trial
|
Lin C.-C.;Hsu C.-H.;Hour T.-C.;Cheng A.-L.;Huang C.-Y.;Huang K.-H.;Chen J.;Yeong-Shiau Pu; Lin C.-C.; Hsu C.-H.; Hour T.-C.; Cheng A.-L.; Huang C.-Y.; Huang K.-H.; Chen J.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-02-02T00:46:57Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Lin C.-C.;Hsu C.-H.;Huang C.-Y.;Keng H.-Y.;Tsai Y.-C.;Huang K.-H.;Cheng A.-L.;Yeong-Shiau Pu; Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Keng H.-Y.; Tsai Y.-C.; Huang K.-H.; Cheng A.-L.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-02-02T00:46:53Z |
Systemic therapy for metastatic urothelial carcinoma
|
Lin C.-C.; Hsu C.-H.; YEONG-SHIAU PU; Vogelzang N.J. |
| 臺大學術典藏 |
2021-02-02T00:46:51Z |
Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma
|
Lin C.-C.; YEONG-SHIAU PU; Hsu C.-H.; Keng H.-Y.; Cheng A.-L.; Yang C.-H. |
| 臺大學術典藏 |
2021-02-02T00:46:47Z |
Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder Cancer
|
Lin C.-C.; Hsu C.-H.; Cheng J.C.; Huang C.-Y.; Tsai Y.-C.; Hsu F.-M.; Huang K.-H.; Cheng A.-L.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-02-02T00:46:29Z |
Celecoxib-induced cytotoxic effect is potentiated by inhibition of autophagy in human urothelial carcinoma cells
|
Huang K.-H.; Kuo K.-L.; Ho I.-L.; Chang H.-C.; Chuang Y.-T.; Lin W.-C.; Lee P.-Y.; Chang S.-C.; Chiang C.-K.; YEONG-SHIAU PU; Chou C.-T.; Hsu C.-H.; Liu S.-H. |
| 臺大學術典藏 |
2021-02-02T00:46:21Z |
MLN4924, a novel protein neddylation inhibitor, suppresses proliferation and migration of human urothelial carcinoma: In vitro and in vivo studies
|
Kuo K.-L.;Ho I.-L.;Shi C.-S.;Wu J.-T.;Lin W.-C.;Tsai Y.-C.;Chang H.-C.;Chou C.-T.;Hsu C.-H.;Hsieh J.-T.;Chang S.-C.;Yeong-Shiau Pu;Huang K.-H.; Kuo K.-L.; Ho I.-L.; Shi C.-S.; Wu J.-T.; Lin W.-C.; Tsai Y.-C.; Chang H.-C.; Chou C.-T.; Hsu C.-H.; Hsieh J.-T.; Chang S.-C.; YEONG-SHIAU PU; Huang K.-H. |
| 臺大學術典藏 |
2021-02-02T00:46:17Z |
MLN4924 synergistically enhances cisplatin-induced cytotoxicity via jnk and bcl-xl pathways in human urothelial carcinoma
|
Ho I.-L.;Kuo K.-L.;Liu S.-H.-.;Chang H.-C.;Hsieh J.-T.;Wu J.-T.;Chiang C.-K.;Lin W.-C.;Tsai Y.-C.;Chou C.-T.;Hsu C.-H.;Yeong-Shiau Pu;Shi C.-S.;Huang K.-H.; Ho I.-L.; Kuo K.-L.; Liu S.-H.-.; Chang H.-C.; Hsieh J.-T.; Wu J.-T.; Chiang C.-K.; Lin W.-C.; Tsai Y.-C.; Chou C.-T.; Hsu C.-H.; YEONG-SHIAU PU; Shi C.-S.; Huang K.-H. |
| 臺大學術典藏 |
2021-02-02T00:46:08Z |
A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement
|
Chiang Y.;Cheng J.C.-H.;Huang C.-Y.;Tsai Y.-C.;Lin C.-C.;Hsu C.-H.;Cheng A.-L.;Yeong-Shiau Pu; Chiang Y.; Cheng J.C.-H.; Huang C.-Y.; Tsai Y.-C.; Lin C.-C.; Hsu C.-H.; Cheng A.-L.; YEONG-SHIAU PU |
| 臺大學術典藏 |
2021-01-28T03:15:20Z |
Suppression of Angiogenesis by Targeting Cyclin-Dependent Kinase 7 in Human Umbilical Vein Endothelial Cells and Renal Cell Carcinoma: An In Vitro and In Vivo Study
|
Shi C.-S.;Kuo K.-L.;Chen M.-S.;Po-Ming Chow;Liu S.-H.;Chang Y.-W.;Lin W.-C.;Liao S.-M.;Hsu C.-H.;Hsu F.-S.;Chang H.-C.;Huang K.-H.; Shi C.-S.; Kuo K.-L.; Chen M.-S.; PO-MING CHOW; Liu S.-H.; Chang Y.-W.; Lin W.-C.; Liao S.-M.; Hsu C.-H.; Hsu F.-S.; Chang H.-C.; Huang K.-H. |
| 臺大學術典藏 |
2021-01-28T03:15:20Z |
The Deubiquitinating Enzyme Inhibitor PR-619 Enhances the Cytotoxicity of Cisplatin via the Suppression of Anti-Apoptotic Bcl-2 Protein: In Vitro and In Vivo Study
|
Kuo K.-L.;Liu S.-H.;Lin W.-C.;Po-Ming Chow;Chang Y.-W.;Yang S.-P.;Shi C.-S.;Hsu C.-H.;Liao S.-M.;Chang H.-C.;Huang K.-H.; Kuo K.-L.; Liu S.-H.; Lin W.-C.; PO-MING CHOW; Chang Y.-W.; Yang S.-P.; Shi C.-S.; Hsu C.-H.; Liao S.-M.; Chang H.-C.; Huang K.-H. |
| 臺大學術典藏 |
2021-01-28T02:03:54Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Keng H.-Y.; Tsai Y.-C.; KUO-HOW HUANG; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2021-01-28T02:03:54Z |
Prognostic Factors for Metastatic Urothelial Carcinoma Treated with Cisplatin and 5-Fluorouracil-Based Regimens
|
Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Tsai Y.-C.; KUO-HOW HUANG; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2021-01-28T02:03:53Z |
Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trial
|
Lin C.-C.;Hsu C.-H.;Hour T.-C.;Cheng A.-L.;Huang C.-Y.;Kuo-How Huang;Chen J.;Pu Y.-S.; Lin C.-C.; Hsu C.-H.; Hour T.-C.; Cheng A.-L.; Huang C.-Y.; KUO-HOW HUANG; Chen J.; Pu Y.-S. |
| 臺大學術典藏 |
2021-01-28T02:03:44Z |
Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder Cancer
|
Lin C.-C.; Hsu C.-H.; Cheng J.C.; Huang C.-Y.; Tsai Y.-C.; Hsu F.-M.; KUO-HOW HUANG; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2021-01-28T02:03:27Z |
Celecoxib-induced cytotoxic effect is potentiated by inhibition of autophagy in human urothelial carcinoma cells
|
Kuo-How Huang;Kuo K.-L.;Ho I.-L.;Chang H.-C.;Chuang Y.-T.;Lin W.-C.;Lee P.-Y.;Chang S.-C.;Chiang C.-K.;Pu Y.-S.;Chou C.-T.;Hsu C.-H.;Liu S.-H.; KUO-HOW HUANG; Kuo K.-L.; Ho I.-L.; Chang H.-C.; Chuang Y.-T.; Lin W.-C.; Lee P.-Y.; Chang S.-C.; Chiang C.-K.; Pu Y.-S.; Chou C.-T.; Hsu C.-H.; Liu S.-H. |
| 臺大學術典藏 |
2021-01-28T02:03:22Z |
MLN4924, a novel protein neddylation inhibitor, suppresses proliferation and migration of human urothelial carcinoma: In vitro and in vivo studies
|
Kuo K.-L.;Ho I.-L.;Shi C.-S.;Wu J.-T.;Lin W.-C.;Tsai Y.-C.;Chang H.-C.;Chou C.-T.;Hsu C.-H.;Hsieh J.-T.;Chang S.-C.;Pu Y.-S.;Kuo-How Huang; Kuo K.-L.; Ho I.-L.; Shi C.-S.; Wu J.-T.; Lin W.-C.; Tsai Y.-C.; Chang H.-C.; Chou C.-T.; Hsu C.-H.; Hsieh J.-T.; Chang S.-C.; Pu Y.-S.; KUO-HOW HUANG |
| 臺大學術典藏 |
2021-01-28T02:03:18Z |
MLN4924 synergistically enhances cisplatin-induced cytotoxicity via jnk and bcl-xl pathways in human urothelial carcinoma
|
Ho I.-L.;Kuo K.-L.;Liu S.-H.-.;Chang H.-C.;Hsieh J.-T.;Wu J.-T.;Chiang C.-K.;Lin W.-C.;Tsai Y.-C.;Chou C.-T.;Hsu C.-H.;Pu Y.-S.;Shi C.-S.;Kuo-How Huang; Ho I.-L.; Kuo K.-L.; Liu S.-H.-.; Chang H.-C.; Hsieh J.-T.; Wu J.-T.; Chiang C.-K.; Lin W.-C.; Tsai Y.-C.; Chou C.-T.; Hsu C.-H.; Pu Y.-S.; Shi C.-S.; KUO-HOW HUANG |
| 臺大學術典藏 |
2021-01-28T02:02:58Z |
Epigallocatechin Gallate Attenuates Partial Bladder Outlet Obstruction-induced Bladder Injury via Suppression of Endoplasmic Reticulum Stress-related Apoptosis - In Vivo Study
|
Hsieh J.-T.; Kuo K.-L.; Liu S.-H.; Shi C.-S.; Chang H.-C.; Lin W.-C.; Chou C.-T.; Hsu C.-H.; Liao S.-M.; Wang Z.-H.; Li C.-C.; KUO-HOW HUANG |
| 臺大學術典藏 |
2021-01-28T02:02:45Z |
Trifluoperazine, an antipsychotic drug, effectively reduces drug resistance in cisplatin-resistant urothelial carcinoma cells via suppressing bcl-xl: An in vitro and in vivo study
|
Kuo K.-L.;Liu S.-H.;Lin W.-C.;Hsu F.-S.;Chow P.-M.;Chang Y.-W.;Yang S.-P.;Shi C.-S.;Hsu C.-H.;Liao S.-M.;Chang H.-C.;Kuo-How Huang; Kuo K.-L.; Liu S.-H.; Lin W.-C.; Hsu F.-S.; Chow P.-M.; Chang Y.-W.; Yang S.-P.; Shi C.-S.; Hsu C.-H.; Liao S.-M.; Chang H.-C.; KUO-HOW HUANG |
| 臺大學術典藏 |
2021-01-28T02:02:44Z |
The Deubiquitinating Enzyme Inhibitor PR-619 Enhances the Cytotoxicity of Cisplatin via the Suppression of Anti-Apoptotic Bcl-2 Protein: In Vitro and In Vivo Study
|
Kuo K.-L.;Liu S.-H.;Lin W.-C.;Chow P.-M.;Chang Y.-W.;Yang S.-P.;Shi C.-S.;Hsu C.-H.;Liao S.-M.;Chang H.-C.;Kuo-How Huang; Kuo K.-L.; Liu S.-H.; Lin W.-C.; Chow P.-M.; Chang Y.-W.; Yang S.-P.; Shi C.-S.; Hsu C.-H.; Liao S.-M.; Chang H.-C.; KUO-HOW HUANG |
| 臺大學術典藏 |
2021-01-28T02:02:43Z |
Suppression of Angiogenesis by Targeting Cyclin-Dependent Kinase 7 in Human Umbilical Vein Endothelial Cells and Renal Cell Carcinoma: An In Vitro and In Vivo Study
|
Shi C.-S.;Kuo K.-L.;Chen M.-S.;Chow P.-M.;Liu S.-H.;Chang Y.-W.;Lin W.-C.;Liao S.-M.;Hsu C.-H.;Hsu F.-S.;Chang H.-C.;Kuo-How Huang; Shi C.-S.; Kuo K.-L.; Chen M.-S.; Chow P.-M.; Liu S.-H.; Chang Y.-W.; Lin W.-C.; Liao S.-M.; Hsu C.-H.; Hsu F.-S.; Chang H.-C.; KUO-HOW HUANG |
| 臺大學術典藏 |
2021-01-28T01:07:01Z |
Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers
|
Hsu C.-H.;Kun-Huei Yeh;Chen L.-T.;Liu J.M.;Jan C.-M.;Lin J.-T.;Chen Y.-C.;Cheng A.-L.; Hsu C.-H.; KUN-HUEI YEH; Chen L.-T.; Liu J.M.; Jan C.-M.; Lin J.-T.; Chen Y.-C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:07:00Z |
Thymic carcinoma with autoimmune syndrome: Successful treatment with weekly infusional high-dose 5-fluorouracil and leucovorin
|
Hsu C.-H.;Kun-Huei Yeh;Cheng A.-L.; Hsu C.-H.; KUN-HUEI YEH; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:07:00Z |
A phase II study of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (HDFL) in the treatment of recurrent or metastatic colorectal cancers
|
Kun-Huei Yeh;Cheng A.-L.;Lin M.-T.;Hong R.-L.;Hsu C.-H.;Lin J.-F.;Chang K.-J.;Lee P.-H.;Chen Y.-C.; KUN-HUEI YEH; Cheng A.-L.; Lin M.-T.; Hong R.-L.; Hsu C.-H.; Lin J.-F.; Chang K.-J.; Lee P.-H.; Chen Y.-C. |
| 臺大學術典藏 |
2021-01-28T01:06:55Z |
Concurrent chemoradiotherapy for locally advanced esophageal cancer - A pilot study by using daily low-dose cisplatin and continuous infusion of 5-fluorouracil
|
Hsu C.-H.;Kun-Huei Yeh;Lui L.T.;Lee Y.-C.;Bu C.-F.;Wang H.-P.;Lin J.-T.;Cheng A.-L.; Hsu C.-H.; KUN-HUEI YEH; Lui L.T.; Lee Y.-C.; Bu C.-F.; Wang H.-P.; Lin J.-T.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:54Z |
Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil
|
Kun-Huei Yeh;Yeh S.-H.;Hsu C.-H.;Wang T.-M.;Ma I.-F.;Cheng A.-L.; KUN-HUEI YEH; Yeh S.-H.; Hsu C.-H.; Wang T.-M.; Ma I.-F.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:53Z |
P53 Overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection
|
Liang J.-T.;Huang K.-C.;Cheng Y.-M.;Hsu H.-C.;Cheng A.-L.;Hsu C.-H.;Kun-Huei Yeh;Wang S.-M.;Chang K.-J.; Liang J.-T.; Huang K.-C.; Cheng Y.-M.; Hsu H.-C.; Cheng A.-L.; Hsu C.-H.; KUN-HUEI YEH; Wang S.-M.; Chang K.-J. |
| 臺大學術典藏 |
2021-01-28T01:06:53Z |
Combination of 13-cis retinoic acid and interferon-α in the treatment of recurrent or refractory peripheral T-cell lymphoma
|
Huang C.-L.;Lin Z.-Z.;Su I.-J.;Chao T.-Y.;Tien H.-F.;Chang M.-C.;Huang M.-C.;Kao W.-Y.;Tang J.-L.;Kun-Huei Yeh;Wang C.-H.;Hsu C.-H.;Liu M.-Y.;Cheng A.-L.; Huang C.-L.; Lin Z.-Z.; Su I.-J.; Chao T.-Y.; Tien H.-F.; Chang M.-C.; Huang M.-C.; Kao W.-Y.; Tang J.-L.; KUN-HUEI YEH; Wang C.-H.; Hsu C.-H.; Liu M.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:52Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Hsu C.-H.;Cheng A.-L.;Hsu C.;Yang C.-H.;Lu Y.-S.;Lin C.-C.;Bu C.-F.;Kun-Huei Yeh; Hsu C.-H.; Cheng A.-L.; Hsu C.; Yang C.-H.; Lu Y.-S.; Lin C.-C.; Bu C.-F.; KUN-HUEI YEH |
| 臺大學術典藏 |
2021-01-28T01:06:52Z |
High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection
|
Liang J.-T.;Huang K.-C.;Lai H.-S.;Lee P.-H.;Cheng Y.-M.;Hsu H.-C.;Cheng A.-L.;Hsu C.-H.;Kun-Huei Yeh;Wang S.-M.;Tang C.;Chang K.-J.; Liang J.-T.; Huang K.-C.; Lai H.-S.; Lee P.-H.; Cheng Y.-M.; Hsu H.-C.; Cheng A.-L.; Hsu C.-H.; KUN-HUEI YEH; Wang S.-M.; Tang C.; Chang K.-J. |
| 臺大學術典藏 |
2021-01-28T01:06:50Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Lu Y.-S.;Hsu C.;Li C.-C.;Kuo S.-H.;Kun-Huei Yeh;Yang C.-H.;Hsu C.-H.;Wu C.-Y.;Cheng A.-L.; Lu Y.-S.; Hsu C.; Li C.-C.; Kuo S.-H.; KUN-HUEI YEH; Yang C.-H.; Hsu C.-H.; Wu C.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:50Z |
Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/ leucovorin for locally advanced or metastatic carcinoma of the biliary tract
|
Hsu C.;Shen Y.-C.;Yang C.-H.;Kun-Huei Yeh;Lu Y.-S.;Hsu C.-H.;Liu H.-T.;Li C.-C.;Chen J.-S.;Wu C.-Y.;Cheng A.-L.; Hsu C.; Shen Y.-C.; Yang C.-H.; KUN-HUEI YEH; Lu Y.-S.; Hsu C.-H.; Liu H.-T.; Li C.-C.; Chen J.-S.; Wu C.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:49Z |
Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer
|
Kun-Huei Yeh;Lu Y.S.;Hsu C.H.;Lin J.F.;Chao H.J.;Huang T.C.;Chung C.Y.;Chang C.S.;Yang C.H.;Cheng A.L.; KUN-HUEI YEH; Lu Y.S.; Hsu C.H.; Lin J.F.; Chao H.J.; Huang T.C.; Chung C.Y.; Chang C.S.; Yang C.H.; Cheng A.L. |
| 臺大學術典藏 |
2021-01-28T01:06:48Z |
Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer
|
Kun-Huei Yeh;Lu Y.-S.;Hsu C.-H.;Lin J.-F.;Hsu C.;Kuo S.-H.;Li Jr. S.;Cheng A.-L.; KUN-HUEI YEH; Lu Y.-S.; Hsu C.-H.; Lin J.-F.; Hsu C.; Kuo S.-H.; Li Jr. S.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:48Z |
Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and paclitaxel as first-line treatment
|
Yang C.-H.;Chen M.-C.;Cheng A.-L.;Hsu C.-H.;Kun-Huei Yeh;Yu Y.-C.;Whang-Peng J.;Yang P.-C.; Yang C.-H.; Chen M.-C.; Cheng A.-L.; Hsu C.-H.; KUN-HUEI YEH; Yu Y.-C.; Whang-Peng J.; Yang P.-C. |
| 臺大學術典藏 |
2021-01-28T01:06:47Z |
A pathway for tumor necrosis factor-α-induced Bcl10 nuclear translocation: Bcl10 is up-regulated by NF-κB and phosphorylated by Akt1 and then complexes with Bcl3 to enter the nucleus
|
Pei Y.Y.;Kuo S.-H.;Kun-Huei Yeh;Chuang S.-E.;Hsu C.-H.;Wen C.C.;Lin H.-I.;Gao M.;Cheng A.-L.; Pei Y.Y.; Kuo S.-H.; KUN-HUEI YEH; Chuang S.-E.; Hsu C.-H.; Wen C.C.; Lin H.-I.; Gao M.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:46Z |
Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer
|
Lin C.-C.;Hsu C.-H.;Cheng J.C.;Wang H.-P.;Lee J.-M.;Kun-Huei Yeh;Yang C.-H.;Lin J.-T.;Cheng A.-L.;Lee Y.-C.; Lin C.-C.; Hsu C.-H.; Cheng J.C.; Wang H.-P.; Lee J.-M.; KUN-HUEI YEH; Yang C.-H.; Lin J.-T.; Cheng A.-L.; Lee Y.-C. |
| 臺大學術典藏 |
2021-01-28T01:06:45Z |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
|
Lin C.-C.;Kun-Huei Yeh;Yang C.-H.;Hsu C.;Tsai Y.-C.;Hsu W.-L.;Cheng A.-L.;Hsu C.-H.; Lin C.-C.; KUN-HUEI YEH; Yang C.-H.; Hsu C.; Tsai Y.-C.; Hsu W.-L.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-01-28T01:06:45Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Lin C.-C.;Cheng A.-L.;Hsu C.-H.;Lu Y.-S.;Hsu C.;Kun-Huei Yeh;Wu C.-Y.;Huang C.-S.;Yang C.-H.; Lin C.-C.; Cheng A.-L.; Hsu C.-H.; Lu Y.-S.; Hsu C.; KUN-HUEI YEH; Wu C.-Y.; Huang C.-S.; Yang C.-H. |
| 臺大學術典藏 |
2021-01-28T01:06:44Z |
Weekly 24-hour infusional 5-fluorouracil as initial treatment for advanced gastric cancer with acute disseminated intravascular coagulation
|
Huang T.-C.; KUN-HUEI YEH; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-01-28T01:06:42Z |
Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001
|
Kuo S.-H.;Hsu C.-H.;Chen L.-T.;Lu Y.-S.;Lin C.-H.;Yeh P.-Y.;Jeng H.-J.;Gao M.;Kun-Huei Yeh;Cheng A.-L.; Kuo S.-H.; Hsu C.-H.; Chen L.-T.; Lu Y.-S.; Lin C.-H.; Yeh P.-Y.; Jeng H.-J.; Gao M.; KUN-HUEI YEH; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:40Z |
T(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement
|
Kuo S.-H.;Cheng A.-L.;Lin C.-W.;Hsu C.-H.;Wu M.-S.;Kun-Huei Yeh;Tzeng Y.-S.;Chen L.-T.; Kuo S.-H.; Cheng A.-L.; Lin C.-W.; Hsu C.-H.; Wu M.-S.; KUN-HUEI YEH; Tzeng Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2021-01-28T01:06:39Z |
Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer
|
Lu L.-C.; Shao Y.-Y.; Hsu C.-H.; Hsu C.; Cheng W.-F.; Lin Y.-L.; Cheng A.-L.; KUN-HUEI YEH |
| 臺大學術典藏 |
2021-01-28T01:06:36Z |
Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy
|
Chen W.-W.;Lin C.-C.;Huang T.-C.;Cheng A.-L.;Kun-Huei Yeh;Hsu C.-H.; Chen W.-W.; Lin C.-C.; Huang T.-C.; Cheng A.-L.; KUN-HUEI YEH; Hsu C.-H. |
| 臺大學術典藏 |
2021-01-28T01:06:32Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C.; Su W.-C.; Yen C.-J.; Hsu C.-H.; Su W.-P.; KUN-HUEI YEH; Lu Y.-S.; Cheng A.-L.; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-01-28T01:06:29Z |
Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan
|
Shao Y.-Y.; Hsu C.-H.; KUN-HUEI YEH; Chen H.-M.; Yeh Y.-C.; Lai C.-L.; Lin Z.-Z.; Cheng A.-L.; Lai M.-S. |
